Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Therapeutic drug monitoring and virological response at week 48 in a cohort of HIV-1-infected patients switching to dolutegravir/rilpivirine dual maintenance therapy (ANRS-MIE-BIRIDER study).
Lemaitre F, Lagoutte-Renosi J, Gagnieu MC, Parant F, Venisse N, Grégoire M, Bouchet S, Garraffo R, Lê MP, Muret P, Comets E, Solas C, Peytavin G; ANRS-MIE-BIRIDER Study group on behalf of the Clinical Pharmacology Group of ANRS-MIE AC43. Lemaitre F, et al. Among authors: le mp. Br J Clin Pharmacol. 2024 Jan;90(1):264-273. doi: 10.1111/bcp.15890. Epub 2023 Sep 18. Br J Clin Pharmacol. 2024. PMID: 37602480 Free article.
Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals.
Lê MP, Belarbi L, Chaix ML, Dulioust E, Mahjoub N, Salmon D, Viard JP, Duvivier C, Peytavin G, Launay O, Ghosn J. Lê MP, et al. J Antimicrob Chemother. 2017 Nov 1;72(11):3167-3171. doi: 10.1093/jac/dkx275. J Antimicrob Chemother. 2017. PMID: 28961979
High virological suppression regardless of the genotypic susceptibility score after switching to a dolutegravir-based regimen: week 48 results in an observational cohort.
Charpentier C, Peytavin G, Lê MP, Joly V, Cabras O, Perrier M, Le Gac S, Phung B, Yazdanpanah Y, Descamps D, Landman R. Charpentier C, et al. Among authors: le mp, le gac s. J Antimicrob Chemother. 2018 Jun 1;73(6):1665-1671. doi: 10.1093/jac/dky062. J Antimicrob Chemother. 2018. PMID: 29528412
Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study.
Lê MP, Chaix ML, Chevret S, Bertrand J, Raffi F, Gallien S, El Abbassi EMB, Katlama C, Delobel P, Yazdanpanah Y, Saillard J, Molina JM, Peytavin G; ANRS 165 DARULIGHT Study Group. Lê MP, et al. J Antimicrob Chemother. 2018 Aug 1;73(8):2120-2128. doi: 10.1093/jac/dky193. J Antimicrob Chemother. 2018. PMID: 29905808 Clinical Trial.
Pharmacovirological analyses of blood and male genital compartment in patients receiving dolutegravir + lamivudine dual therapy as a switch strategy (ANRS 167 LAMIDOL trial).
Charpentier C, Peytavin G, Raffi F, Burdet C, Landman R, Lê MP, Katlama C, Collin G, Benalycherif A, Cabie A, Mentré F, Yazdanpanah Y, Descamps D, Joly V. Charpentier C, et al. Among authors: le mp. J Antimicrob Chemother. 2020 Jun 1;75(6):1611-1617. doi: 10.1093/jac/dkaa035. J Antimicrob Chemother. 2020. PMID: 32091102 Clinical Trial.
124 results